RARX On Other Exchanges

ra pharmaceuticals inc (RARX) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ra pharmaceuticals inc (RARX) Related Businessweek News

No Related Businessweek News Found

ra pharmaceuticals inc (RARX) Details

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company’s peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company’s pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

72 Employees
Last Reported Date: 03/7/19
Founded in 2008

ra pharmaceuticals inc (RARX) Top Compensated Officers

Co-Founder, President, CEO & Director
Total Annual Compensation: $838.3K
Executive VP & CFO
Total Annual Compensation: $585.3K
Chief Medical Officer
Total Annual Compensation: $610.0K
Compensation as of Fiscal Year 2018.
ra pharmaceuticals inc
Ra Pharmaceuticals, Inc. Approves Appointment of Deloitte & Touche LLP as Independent Registered Public Accounting Firm for the Year Ending December 31, 2019

Ra Pharmaceuticals, Inc. approved the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the year ending December 31, 2019, at its Annual Meeting of Stockholders held on June 11, 2019.

Ra Pharmaceuticals Announces Expansion of Neuromuscular Portfolio with Clearance of IND Application for Zilucoplan for the Treatment of Immune-Mediated Necrotizing Myopathy

Ra Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration’s (FDA) clearance of the Company’s Investigational New Drug (IND) application for zilucoplan for the treatment of immune-mediated necrotizing myopathy (IMNM). The Company is on track to initiate a Phase 2 clinical trial in the second half of 2019. IMNM is an autoimmune myopathy characterized by skeletal muscle necrosis, severe proximal limb weakness, and elevated creatine kinase (CK) levels. IMNM is categorized into two subtypes defined by the presence of distinct autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) or signal recognition particle (SRP). In IMNM, these autoantibodies drive complement-mediated necrosis of muscle fibers, resulting in severe, progressive, and debilitating proximal muscle weakness. IMNM affects more than 15,000 patients in the United States, European Union, and Japan. There are currently no approved therapies for the treatment of IMNM. The randomized, double-blind, placebo-controlled, multi-center, Phase 2 trial will evaluate the safety, tolerability, and efficacy of zilucoplan in patients with IMNM who are positive for anti-HMGCR or anti-SRP autoantibodies. Patients will be randomized in a 1:1 ratio to receive daily subcutaneous (SC) doses of 0.3 mg/kg zilucoplan or placebo. Randomization will be stratified based on antibody status (anti-HMGCR+ versus anti-SRP+). The trial is expected to enroll approximately 24 patients with an eight-week treatment period. The primary endpoint will be change in CK from baseline to week eight. Following completion of the trial, patients will have the option to enter into an open-label long-term extension study with zilucoplan.

Ra Pharmaceuticals, Inc. - Special Call

Ra Pharmaceuticals, Inc. - Special Call


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

RARX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RARX.
View Industry Companies

Industry Analysis


Industry Average

Valuation RARX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 442.3x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 365.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact RA PHARMACEUTICALS INC, please visit rapharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.